Company number: 05498067 Charity Number: 1113263 

## International Federation of Gynecology and Obstetrics 

Report and financial statements For the year ended 31 December 2021 




International Federation of Gynecology and Obstetrics 

## Contents 

For the year ended 31 December 2021 

Reference and administrative information  ...................................................................................... 1 Trustees’ annual report  .................................................................................................................. 3 Independent auditor’s report  ....................................................................................................... 18 Consolidated statement of financial activities  .............................................................................. 23 Balance sheets  .............................................................................................................................. 24 Consolidated statement of cash flows ........................................................................................... 25 Notes to the financial statements  ................................................................................................. 26 



International Federation of Gynecology and Obstetrics 

## Reference and administrative information 

For the year ended 31 December 2021 

Company number 05498067 Charity number 1113263 Registered office and operational address FIGO House, Suite 3 - Waterloo Court, 10 Theed Street, London SE1 8ST Country of registration England & Wales Country of incorporation United Kingdom Disclose any other name that the charitable company uses ‘FIGO’ 

Trustees Trustees, who are also directors under company law, who served during the year and up to the date of this report were as follows: 

To 28[th] October 2021 Dr. Carlos Fuchtner President Dr. Faysal El Kak Vice President Dr. Ralph Hale Honorary Treasurer Prof. Dame Lesley Regan Honorary Secretary Dr. Jeanne Conry President Elect Prof. CN Purandare Past President 

From 28[th] October 2021 Dr. Jeanne Conry President Prof. Philippe Descamps Vice President Prof. Shantha Kumari Sekaran Honorary Treasurer Prof. Dame Lesley Regan Honorary Secretary Dr. Anne Beatrice Kihara President Elect Dr. Edgar Ivan Ortiz Lizcano Regional Trustee Dr. Muna Tahlak Regional Trustee Prof. Basil Tarlatzis Regional Trustee Dr. Ravi Chandran Regional Trustee Dr. Jennifer Mary Blake Regional Trustee 

Key management personnel 

Prof. Mary Ann Lumsden Chief Executive Sean O’Donnell Deputy CEO Stewart Gilmour Director of Finance & IT (until 30 July 2021) Hani Fawzi Director of Projects 

1 



International Federation of Gynecology and Obstetrics 

## Reference and administrative information 

For the year ended 31 December 2021 

Bankers HSBC 431 Oxford St, London W1C 2DA Solicitors Davies & Partners 57 Queen Anne Street, London W1G 9JR Hempsons 100 Wood Street, London, EC2V 7AN Auditor Sayer Vincent LLP Chartered Accountants and Statutory Auditor Invicta House 108-114 Golden Lane LONDON EC1Y 0TL 

2 



International Federation of Gynecology and Obstetrics 

## Trustees’ report 

For the year ended 31 December 2021 

The trustees present their report and the audited financial statements for the year ended 31 December 2021. 

Reference and administrative information set out on pages 1 and 2 forms part of this report. The financial statements comply with current statutory requirements, the memorandum and articles of association and the Statement of Recommended Practice - Accounting and Reporting by Charities: SORP applicable to charities preparing their accounts in accordance with FRS 102. 

## Objectives and activities 

## Purposes and aims 

The charity’s object , for which FIGO is established, is restricted to the promotion of the health, wellbeing and rights of women worldwide by ensuring high standards in the practice of gynaecology and obstetrics for the benefit of the public. 

The main activities undertaken by the Charity to further its charitable object for the public benefit include but are not limited to: 

- Projects aimed at improving women’s health, wellbeing and rights in low and middleincome countries including safe motherhood projects designed to reduce maternal mortality as well as sexual and reproductive health. 

- The awarding of modest grants to FIGO Committees and National Societies to help in the promotion of the health and wellbeing of women worldwide and to improve the practice of gynecology and obstetrics. 

- The organisation of international workshops and meetings. 

- The production of educational material relating to women’s health and the practice of obstetrics and gynaecology. These include webinars, Guidelines and other Best Practice advice. 

The activities of the subsidiary, FIGO Trading Limited , include but are not limited to: 

- The organisation of a World Congress of Gynecology and Obstetrics held every two years. 

- The production of the International Journal of Gynecology & Obstetrics and other FIGO publications. 

3 



International Federation of Gynecology and Obstetrics 

## Trustees’ report 

## For the year ended 31 December 2021 

## The Charity is committed to: 

- Encouraging all efforts for raising the status of women and for advancing their role in all issues related to women’s health. 

- Promoting sexual and reproductive health and rights and services through education, research and advocacy that will support the provision of accessible, efficient, affordable, sustainable comprehensive reproductive health services. 

- Accelerating its efforts and activities in respect of the United Nations’ Sustainable Development Goals (SDG) and to achieving these targets especially in the area of safe motherhood and new-born health and gender equality. 

- Continually upgrading the practice of gynaecology and obstetrics through research implementation, education and training and by maintaining the highest levels of professionalism and scientific and ethical standards. 

- Improving communication with and between Society Member associations and building the capacities of those from low-resource countries through strengthening leadership, management, good practice and the promotion of policy dialogues. 

- Strengthening capacities to enable Society Member associations to play a pivotal role in the development and implementation of sustainable programmes aimed at the improvement of care available to women and new-borns especially for poor and underserved populations. These include developing their abilities to advocate on behalf of women and those who care for them to policy makers at regional and national level. 

- Recognising the importance of collaborative efforts for advancing women’s health and rights, the Charity is committed to strengthening partnerships with other international professional organisations, UN agencies, and the public/private sector to achieve its objectives. 

## Public Benefit Statement 

The trustees have referred to the guidance contained in the Charity Commission's general guidance on public benefit when reviewing the charity's aims and objectives and in planning its future activities. In particular, the trustees consider how planned activities will contribute to the aims and objectives that have been set. 

4 



International Federation of Gynecology and Obstetrics 

## Trustees’ report 

For the year ended 31 December 2021 

The trustees review the aims, objectives and activities of the charity each year. This report looks at what the charity has achieved and the outcomes of its work in the reporting period. The trustees report the success of each key activity and the benefits the charity has brought to those groups of people that it is set up to help. 

## Achievements and performance 

The charity's main activities and who it tries to help are described below. All its charitable activities focus on the improvement of women's health and reproductive rights, the reduction of disparities in healthcare available to women and new-borns, as well as advancing the science and practice of gynaecology and obstetrics and are undertaken to further FIGO’s charitable purposes for the public benefit. 

The Charity is the only global organisation that brings together professional societies of obstetricians and gynaecologists from across the world. The Charity currently has Society Member associations in 135 countries/territories. 

## Restricted projects 

The Charity has been fortunate to receive a number of large grants to fund specific multi-year projects. These include projects aimed to improve the health and wellbeing of all women whether pregnant or non-pregnant and the services that support this in low- and middleresource countries/territories. FIGO works with its Member associations to deliver improved health interventions or helps the Member associations build capacity and capability in a particular region or nation. 

FIGO currently has a number of large projects in progress and received money to support its activities from donors totalling £5,195,509 during 2021 (2020: £4,716,043), including £3,800,271 (2020: £2,817,979) for the project relating to Advocating Safe Abortion, which is currently being delivered in ten countries, £487,439 (2020: £303,285) for our Fistula Surgery Training Initiative and also £469,727 (2020: £643,812) for the project relating to Combatting Post-Partum Haemorrhage (CPH). 

These specific restricted projects are normally undertaken only as and when funding becomes available, and a project generally takes place over the term of the grant funding which is typically between one and three years. FIGO always aims to demonstrate positive and sustainable outcomes from its projects in improving maternal health. Evidence of strong outcomes can also help FIGO to secure further grant funding to expand a project’s activities to other countries or to reach greater numbers of women and healthcare professionals. 

Project activities are continuously monitored and evaluated in line with the project objectives and the requirements of the funder. During 2021, projects delivered the following significant achievements: 

5 



International Federation of Gynecology and Obstetrics 

## Trustees’ report 

For the year ended 31 December 2021 

## Advocating for Safe Abortion Project (ASA) 

The Advocating for Safe Abortion Project (ASAP) was recently extended for an additional 12 months making it a four-year project (April 2019 – 2023) with the aim to raise the capacity of ten National Member Societies to be national leaders on sexual and reproductive health and rights, and in advocating for access to safe abortion. The ten countries involved in 2021 are Benin, Cameroon, Ivory Coast, Kenya, Mali, Mozambique, Panama, Peru, Uganda, and Zambia. The project also involves international advocacy and communications by FIGO on the issue. 

The third year of the project has seen successful implementation of the project through the five strategies: 

- 1) strengthening the management and organisation of the society, 

- 2) establishing coordinated and vibrant national networks of associations, 

- 3) creating increased acceptance of safe abortion among health workers, policy makers and the general population, 

- 4) ensuring that the policy environment is conducive and providing guidance on the legal framework, 

- 5) ensuring a process for data generation and use for improved monitoring, planning for services, and ensuring advocacy efforts are evidence-based, and 

- 6) Contributing to the advocacy measures that brought about change in the law governing provision of Abortion in Benin. 

The country teams, and FIGO ASAP team have managed to progress well, continuing to adapt where necessary due to the pandemic. The central pillar of institutional strengthening of the societies in a sustainable way has been emphasised with many societies establishing solid governance and organisational structures, setting up committees and regional offices, and strengthening partnerships with key stakeholder including Ministry of Health. Attitude change work with healthcare providers, cultural and religious leaders and others continues to yield great results. FIGO support to the societies has included training streams on social media, high impact learning, monitoring behaviour change, HR management, research methodology, and resource mobilization. Some highlights of last year’s international work include: representation at FIGO virtual World Congress, high impact International statements and webinars, collaborations on strategic litigations, campaigns and utilisation of UN mechanisms, activities marking International Safe Abortion Day and 16 Days of Activism against Gender-based Violence. 

Fistula Surgery Training Initiative – Texas Children’s Hospital (TCH) and an anonymous foundation 

FIGO plays a crucial role in maternal and new-born health by addressing obstetric fistula, a lifeshattering birth injury caused by unrelieved obstructed labour. It affects the most disadvantaged women in low resource settings and leads to chronic leakage of urine and/or faecal matter. Without a trained, competent fistula surgeon to repair the injury, a woman with 

6 



International Federation of Gynecology and Obstetrics 

## Trustees’ report 

## For the year ended 31 December 2021 

an obstetric fistula will be incontinent for the rest of her life, causing unimaginable suffering and stigmatisation, as well as calamitous social and economic consequences. Obstetric fistula can be prevented by making quality maternal health services available for all, especially emergency caesarean sections (C-sections). Yet, tragically, the condition continues to devastate the lives of 50,000 to 100,000 women every year in 60 of the world’s low-resource countries. This adds to the backlog of one to two million women still suffering with the condition, due to the lack of well-trained, competent fistula surgeons. Recognising obstetric fistula as a neglected public health issue and to bridge the global treatment gap, in 2012 FIGO launched an ambitious Training Programme to greatly increase the number of fistula surgeons. The programme builds the capacities of ‘FIGO Fellows’ - trainee fistula surgeons from fistula-affected countries – starting with initial training in a FIGO Accredited Training Centre and subsequent coaching sessions by expert FIGO Trainers. The Initiative has expanded substantially since its early days, and there are presently 64 Fellows from 23 high-need countries in sub-Saharan Africa and Asia being trained as fistula surgeons, as well as multiple fistula care teams who have also received FIGO training. 

As the COVID-19 pandemic evolved, with the associated international travel restrictions, inperson training took place much less than normal in 2021, but in the second half of the year, new Fellows from Tanzania (2) and from the Democratic Republic of the Congo (1) undertook training placements in the CCBRT Training Centre in Tanzania. 

The reduced training activity in 2021 meant that the project team and Expert Advisory Group continued to make excellent progress developing the new FIGO Fistula Surgery Training Manual -due to be published in 2022- which will include new techniques and over 70 innovative medical illustrations. Furthermore, the project co-funded and edited a new fistula nursing book by Ishbel Campbell and FIGO Fellow, Dr Ian Shane Asiimwe. This much awaited book was released in 2021 and was disseminated to Fellows and their teams round the world. As well as distributing new educational resources, 6 fistula instrument sets and 3 surgical head torches were supplied to 3 Fellows in Uganda (2) and the Democratic Republic of the Congo (1) in 2021. 

Despite the ongoing pandemic, the project achieved some notable milestones in 2021. Firstly, over 2,100 fistula repairs were collectively performed by FIGO Fellows, transforming the lives of some of the most vulnerable and hardest to reach women. This is a considerable achievement, especially since Fellows’ facilities cancelled many elective surgeries during the year as different ‘waves’ of Covid-19 affected their communities. Secondly, in the course of 2021, the project received a record number of applications from strong Fellow candidates and a waiting list for 2022 was therefore started. 

The Training Initiative receives funding from Texas Children’s Hospital (TCH). 2021 was year 2 of a 5 year contract with TCH. In addition, in May 2021, a ‘10-10-10 Action Plan and Fund Raising Drive’ were launched with the goal of enlisting 2-3 additional co-funders in order to 

7 



International Federation of Gynecology and Obstetrics 

## Trustees’ report 

## For the year ended 31 December 2021 

expand and secure the programme. Consequently, at the end of 2021, a 3 year funding contract was signed with an anonymous new foundation and at the time of writing, discussions are continuing with 2 other potential co-funders. This has now been achieved with funding from the Hamblin Foundation and two other anonymous donors. 

## Combating Postpartum Haemorrhage (CPH) 

FIGO is working with implementing partners and national societies in 3 countries to raise their capacity to effectively manage PPH through Emergency PPH Care using a Bundle approach. National societies of obstetrics and gynaecology are critical stakeholders in advocating for and building the capacity of national health systems to provide the right care to women, at the right moment. Their technical expertise and close relationships with other partners including the Ministry of Health, are important in galvanizing the commitment to training, rolling out effective treatment packages and ensuring the wider health system environment enables quality care for all women can be provided at the moment it is needed. 

## Improve access to essential medicines to reduce PPH morbidity and mortality (IAP) 

FIGO is working in partnership with ICM to facilitate the adoption of updated WHO PPH Recommendations (2017/2018), at a country level into practice through the dissemination of updated clinical guidelines and protocols. For these recommendations to have a positive impact on PPH prevention and treatment, a system wide approach is needed. The FIGO/ICM collaboration is working with policy makers, health care providers and supply chain experts to support increased availability of quality uterotonics and the antibrinolytic drug, Tranexamic acid (TXA). FIGO and ICM have joined with their member societies/associations in 8 countries, to develop appropriate tools so that frontline clinicians are able to implement the WHO Recommendations in health facilities. 

## Eliminating Cervical Cancer 

Four pilot projects are being funded by FIGO from dormant funds that were re-designated early in 2021. These projects are located in India, Nigeria, Columbia and Nepal and the total funding will be £80,000. A fifth project has not yet started due to decreased availability of vaccine. 

## Committees and working groups 

In October 2021, 3 Divisions and 17 Committees were created comprising 185 Volunteers. The Division of a Maternal and Newborn Health comprises 5 Committees and the joining in 1 division promotes cohesion and prevents duplication of activities. The Committees bring together experts from across the world to share and drive forward best practice in all areas of Women’s Health and reproductive rights, refugee health and violence against women. These committees are very active with regular Webinars, publications and statements. The latter can be used in advocacy initiatives that span the full range of topics in women’s health across the 

8 



International Federation of Gynecology and Obstetrics 

## Trustees’ report 

## For the year ended 31 December 2021 

lifespan. FIGO’s strategy is to fund some expenses of committees from its unrestricted funds and to seek additional funding from donors for additional committee work and working group activities wherever possible. From October 2021, the Post-partum-Haemorrhage Working Group became a Committee and also, Health Systems Strengthening and Respectful Care was created. The International Childbirth Initiative (ICI) was designated a Project. 

## FIGO Trading Company 

The Charity's wholly owned trading subsidiary, FIGO Trading Limited, operates the commercial trading activities on behalf of the Charity, including organising and managing the triennial FIGO World Congress of Gynecology & Obstetrics and publication of the official journal of FIGO, the 'International Journal of Gynecology and Obstetrics' (IJGO). The company made a Profit of £848,122 during the year to 31 December 2021 (2020: £190,524). The company made a gift of £848,122 (2020: £190,524) to the Charity in accordance with its Memorandum of Association. 

## The International Journal of Gynecology & Obstetrics (IJGO) 

The peer-reviewed monthly medical journal of FIGO, 'International Journal of Gynecology and Obstetrics' (IJGO) has published a broad range of articles, supplements and special features throughout the year relevant to Obstetricians, Gynaecologists, and other practitioners and health professionals worldwide. 

The Impact Factor (IF) represents how many times papers published in IJGO were cited in scientific journals during a particular year. The 2021 IF rose sharply to 4.447 (2020: 3.561) – its highest level to date. There has been a substantial increase in the impact factor over the past three years, thanks in large part to the dedication of our Editorial Board, authors and reviewers. 

Many articles are accessed by academic institutional subscribers, and a number of free access and open access articles are downloaded by a wider readership. In 2021 there was a strong increase in downloads, with 1,640,000 accesses from Wiley Online Library (third party usage not available yet), compared with 1,270,000 in 2020. 

## FIGO Congresses 

The XXIII FIGO World Congress was originally planned to take place in Sydney as an in-person event but, due to restrictions as a result of the COVID-19 pandemic, it was instead held virtually, 21-28 October 2021. Pre-Congress workshops also took place virtually every weekend in October in the lead up to the Congress. The time zone of the live Congress programme shifted every two days to target Asia/Oceania, Europe/Africa/Middle East and North/South America time zones. 

9 



International Federation of Gynecology and Obstetrics 

## Trustees’ report 

## For the year ended 31 December 2021 

The online programme featured 200+ hours of content, 800+ speakers and 1,200+ abstracts. This was attended by over 4,700 delegates, 597 of which were complimentary. The total registration revenue for the virtual event was GBP £756,641. 

Across the events industry, sponsorship income is much lower in virtual events compared to in-person meetings. The sponsorship revenue achieved was GBP £574,465. 

The Israel Forum of the FIGO 2021 World Congress was hosted in collaboration with the Israel Society of Obstetrics and Gynecology (ISOG), 25-28 October 2021, at the Inbal Jerusalem Hotel. The first two days of the Israel Forum commenced with panel discussions which were also streamed to the online platform, followed by tours and activities. The next two days included local programming and workshops. The Israel Forum was attended by approximately 300 local delegates, and 17 international delegates. Attendees of the Israel Forum were also required to register for the virtual FIGO 2021 World Congress. 

## Education, Communication and Advocacy Consortium (ECAC) 

This group comprises an Executive and the 4 Regional Trustees. The aim is to facilitate the development of a consistent message from FIGO and all potential publications are reviewed by the Executive (Vice President, President Elect, Head of Communications, CEO). The Committees also communicate their plans for Webinars and publications to ECAC. 

ECAC will oversee Regional implementation activities and development of Continuing Medical Education in the future. 

## Financial review 

The principal funding sources of the group were contribution income from Society Member associations of £381,856 (2020: £412,521), Journal income of £629,988 (2020: £639,995), and restricted grants of £5,195,509 (2020: £4,716,043). Concessions were made for Societies in Lower or Middle Income Countries due to the COVID pandemic as had occurred in 2020. 

The group has incurred expenditure of £4,211,772 (2020: £4,192,415) in respect of restricted fund projects during the year as shown in Note 18 to the accounts. 

The group's unrestricted expenditure for 2021 was £1,878,247 (2020: £1,479,234). The group’s unrestricted surplus (before movements on investments, defined benefit pension schemes and foreign exchange) for 2021 was £669,052 (2020: deficit of £222,842) in this congress year. 

FIGO registered gains of £379,897 (2020: losses of £86,046) on its investment holdings as ultra loose monetary policy led to buoyant capital markets. Income received from investments in 2021 amounted to £86,979 (2020: £87,376). FIGO has transferred its investment holdings from Close Brothers to the management of CCLA. 

10 



International Federation of Gynecology and Obstetrics 

## Trustees’ report 

## For the year ended 31 December 2021 

Other gains were recorded during the year as a result of the significant revaluation of the British pound (GBP) against the US dollar (USD) and the Euro. Foreign exchange gains totalled £56,655 (2020: losses of £299,763). 

Following a period of deep historical analysis and dialogue with the original company donors, some old restricted balances totalling £486,871 (2020: £149,372) were transferred to unrestricted funds during the fiscal period. 

The group’s balance sheet is strong with a closing total unrestricted reserves of £6,501,319 (2020: £4,873,844) and a healthy liquidity provided by cash balances of £4,670,681 (2020: £4,347,197) and investment holdings of £3,225,239 (2020: £2,754,789). Total funds carried forward as at 31 December 2021 were £8,914,788 (2020: £6,790,447) up by £2,124,341. 

FIGO participates in a multi-employer pension scheme. At 31 December 2021, FIGO’s share in the plans surplus amounted to £169,000 (2020: liability of £75,000), however this had to be capped at £nil as FIGO is unable to access the surplus to reduce contributions or obtain a refund. FIGO recorded an actuarial gain of £35,000 (2020: £15,000) during the financial year. Further details on the pension scheme are provided in note 21 to the accounts. 

The Charity adopts a prudent financial policy that aims to ensure that all activities undertaken are efficiently managed in accordance with approved budgets and in accordance with good practice. All expenditure is monitored and payments processed through a system that endeavours to ensure that any possibility of error is minimised. 

## Principal risks and uncertainties 

The trustees perform a review to identify the major risks to which the Charity is exposed on an annual basis and have established systems and procedures to mitigate these risks. These risks include the possibility of adverse currency fluctuations, a reduction in third party grants and donations and an unexpected downturn in attendance at the organisation’s biennial Congress. 

An Audit and Risk Committee was created in October 2021 that will function separately from the Finance Committee that will deal with the overall management of the Finances. 

The risks identified above are managed through a diverse investment strategy, ensuring a professional and effective relationship with the donor community and consideration of alternative revenue streams. The risks associated with the biennial Congress are managed via the Congress Organising Committee which meets several times during the planning period to ensure the successful management of the event (including mitigation of associated risks). Further details are in the COVID 19 paragraph below. 

11 



International Federation of Gynecology and Obstetrics 

## Trustees’ report 

## For the year ended 31 December 2021 

FIGO maintains several foreign currency bank accounts for activities taking place internationally which are funded from donor grants. Expenditure incurred overseas is paid from these foreign currency bank accounts, thereby minimising any currency exposure. 

The group’s principal financial assets are bank balances, trade debtors and investments. 

The group’s credit risk is primarily attributable to its trade debtors. Trade debtors are included in the financial statements net of provision for doubtful debts. There is no significant concentration of credit risks, with exposure spread over a large number of parties. A regular review is performed of available funds to settle debts as they fall due and active management of the trade debtors and creditors balances to ensure sufficient working capital is available to the group. 

## COVID19 

The COVID19 pandemic has had a wide reaching effect on governments, global events and the population. 

As for the various FIGO activities: 

The collection of Society Membership fees are expected to remain steady, as long as individual countries do not become subject to currency restrictions or are faced with financial difficulties. The Trustees have implemented a reduced fees scheme for: 

- a) Lower middle income countries (LMIC) 

- b) Lower Income Countries (LIC) 

It is hoped that the IJGO licence revenue will also be steady although subscriptions from libraries around the world may decrease. 

The FIGO World congress in 2023 will be a physical event held in Paris but with virtual elements. The ability to attend remotely will facilitate the participation of those individuals from LMICs and LICs. It is possible that income will be reduced as a result of the hybrid format. 

On large donor projects, the donors have been content to keep to payment schedules so far, but we shall continually review the situation. 

Covid 19 to decreased in person activities within the projects and payments from the donors were delayed in some instances. 

The FIGO headquarters in London was secured during 2021 and all staff are now working on a hybrid / blended basis with a combination or remote and office working with access to relevant systems being maintained. 

12 



International Federation of Gynecology and Obstetrics 

## Trustees’ report 

For the year ended 31 December 2021 

## Fundraising 

FIGO has not engaged in public fundraising and has not used professional fundraisers or commercial participators. The charity nevertheless is committed to observing all relevant fundraising regulations and codes. There was no non-compliance of these regulations and codes and the charity received no complaints relating to its fundraising practice. 

FIGO HQ has been receiving advice from a Professional Fundraiser in order to identify new sources of funding. Several major donors are moving to a new model where they donate money directly to the region and countries involved in the projects. 

## Reserves policy and going concern 

The organisation aims to retain sufficient free reserves to ensure the continued efficient running of the core elements of the Charity. 

The level of free reserves at any time will be affected by the proximity of the FIGO World Congress of Gynecology and Obstetrics, which now takes place every two years. Profits from the Congress are used to replenish the level of free reserves, to be drawn on to fund core activities of the charity in years when a Congress does not occur. 

The trustees consider that a baseline of free reserves should be maintained to ensure the core functions can continue for two years even in the event that a Congress is not profitable or has to be cancelled and uninsurable losses arise. 

Therefore, the level of reserves will fluctuate year on year but may represent up to two years’ core operating costs (including Payroll, Rent and Information Technology). Based on current and planned levels of expenditure the level of reserves will vary between £2.0m and £4.0m, reducing as a Congress year approaches and depending on the result arising from the Congress. The level of financial reserves is reviewed continually by the Chief Executive and annually by the wider Trustee Board as well as by the organisation's Audit & Finance Committee. 

At 31 December 2021, the group has reserves that are freely available for expending on charitable purposes of £5,406,858 (2020: £3,826,856). This has been calculated as General funds, equating to total reserves, excluding restricted funds, Pensions reserve and Designated funds, which includes the value of tangible fixed assets held for use by the charity. The reserves at 31 December 2021 are above the level required by the reserves policy of £2.2m (i.e. two year’s payroll and information technology costs). 

The trustees have been working with the Chief Executive to develop a new strategic plan to take the organisation forward to 2030. This plan will consider strategic initiatives and funds required, which may be implemented in the coming years and utilise the free reserves in excess of the required level set out in the reserves policy. The strategic plan is available to view on the 

13 



International Federation of Gynecology and Obstetrics 

## Trustees’ report 

For the year ended 31 December 2021 

FIGO website. 

Where the governing body of FIGO has set aside amounts for a particular purpose a Designated Fund is established to record the amount set aside and the related expenditure. In 2020, the Trustees agreed to designate a President’s fund to undertake women’s health projects. At 31 December 2021, the charity had a President’s designated funds of £50,000 (2020: £50,000). 

## Plans for the future 

The Charity aims to continue its charitable activities for the promotion of the health and wellbeing of women and their children and improving the practice of obstetrics and gynaecology, especially in low- and middle-resource countries/territories. As well as maternal and newborn health, we will be focused on Women’s reproductive rights, refugees and Violence Against Women, building capacity of our member societies to help strengthen their voice nationally and be better placed to disseminate knowledge and expertise from FIGO’s Committees and Working Groups. FIGO aims to expand its activities in the areas of education, training and capacity building and reproductive medicine. FIGO will also work in close collaboration with its partner organisations and work together on common projects. FIGO will continue and expand its working relationship with the World Health Organisation and United Nations and be an active partner. 

## Structure, governance and management 

The organisation is a charitable company limited by guarantee, incorporated on 4[th] July 2005 and registered as a charity on 14[th] March 2006. 

The company was established under a memorandum of association, which established the objects and powers of the charitable company and is governed under its articles of association. During 2019 the Articles of Association were rewritten and adopted at an Extraordinary General Meeting held in Manila, Philippines on Tuesday 12[th] November 2019. The Articles of Association were further amended by special resolution at a General Meeting of the Company held on Sunday 6[th] December 2020. 

All trustees give their time voluntarily and receive no benefits from the charity. Any expenses reclaimed from the charity are set out in note 6 to the accounts. 

## Appointment of trustees 

The International Federation of Gynecology and Obstetrics has a single management body, the Board of Trustees, elected by its Society Members at each General Assembly meeting. 

14 



International Federation of Gynecology and Obstetrics 

## Trustees’ report 

For the year ended 31 December 2021 

## Trustee induction and training 

New trustees receive detailed guidance on the organisational and decision-making structure of the organisation as part of their first meeting together with information on their legal and moral obligations as trustees of the charity. 

Trustees regularly consider the latest guidance from the Charity Commission and other relevant bodies on good practice and undertake such training as is recommended to them. 

## Related parties and relationships with other organisations 

The trustees of the charity give their time freely and receive no remuneration other than reimbursement of reasonable out-of-pocket expenses. 

The Charity's wholly owned subsidiary, FIGO Trading Limited, was established to operate the commercial trading activities of the Charity and in each year of operation FIGO Trading Limited gifts its profits to the Charity. 

The Charity has a close relationship with The FIGO Charitable Foundation, a corporation incorporated in the State of Illinois, USA. The Corporation was established for charitable, educational and scientific purposes and during the year to 31 December 2021 its activity has been to raise funds for such purposes on behalf of the Charity. The FIGO charitable foundation receives Donor gifts denominated in shares and sells those shares for cash, which is then remitted to the Charity. 

The Charity also has a relationship with the International Federation of Gynecology and Obstetrics, which was established in Switzerland in accordance with Section 60 of the Swiss Civil Code et seq. On 1 January 2008, the Swiss organisation transferred its assets and activities to the Charity via a deed of gift. The Swiss organisation ceased all activity at that date and is now dormant. 

## Remuneration policy for key management personnel 

The pay and remuneration of the charity’s key management personnel is established through job evaluation, sector benchmarking, availability of funding, recruitment advertising, individuals’ skills, knowledge & experience and relevant salary surveys comparison. The Chief Executive, together with Senior Managers, will review budget availability for all appointments. The President of FIGO reviews the remuneration of the Chief Executive. 

15 



International Federation of Gynecology and Obstetrics 

Trustees’ report 

For the year ended 31 December 2021 

## Statement of responsibilities of the trustees 

The trustees (who are also directors of the International Federation of Gynecology & Obstetrics for the purposes of company law) are responsible for preparing the trustees’ annual report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice). 

Company law requires the trustees to prepare financial statements for each financial year, which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing these financial statements, the trustees are required to: 

- Select suitable accounting policies and then apply them consistently 

- Observe the methods and principles in the Charities SORP 

- Make judgements and estimates that are reasonable and prudent 

- State whether applicable UK Accounting Standards and statements of recommended practice have been followed, subject to any material departures disclosed and explained in the financial statements 

- Prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in operation 

The trustees are responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities. 

In so far as the trustees are aware: 

- There is no relevant audit information of which the charitable company’s auditor is unaware 

- The trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditor is aware of that information 

The trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions. 

Members of the charity guarantee to contribute an amount not exceeding £10 to the assets of the charity in the event of winding up. The total number of such guarantees at 31 December 2021 was 135 (2020: 132). The trustees are members of the charity but this entitles them only to voting rights. The trustees have no beneficial interest in the charity. 

16 



International Federation of Gynecology and Obstetrics 

## Trustees’ report 

For the year ended 31 December 2021 

The trustees’ annual report, prepared in accordance with small company exemptions, has been approved by the trustees on 9[th] August 2022 and signed on their behalf by: 

Dr Jeanne Conry President 

17 



Independent auditor’s report 

To the members of 

## International Federation of Gynecology and Obstetrics 

## Opinion 

We have audited the financial statements of International Federation of Gynecology and Obstetrics (the ‘parent charitable company’) and its subsidiaries (the ‘group’) for the year ended 31 December 2021 which comprise the consolidated statement of financial activities, the group and parent charitable company balance sheets, the consolidated statement of cash flows and the notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice). 

In our opinion, the financial statements: 

- Give a true and fair view of the state of the group’s and of the parent charitable company’s affairs as at 31 December 2021 and of the group’s incoming resources and application of resources, including its income and expenditure, for the year then ended 

- Have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice 

- Have been prepared in accordance with the requirements of the Companies Act 2006 and the Charities Act 2011 

## Basis for opinion 

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor’s responsibilities for the audit of the group financial statements section of our report. We are independent of the group and parent charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion. 

## Conclusions relating to going concern 

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate. 

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charity’s ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue. 

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report. 

18 



Independent auditor’s report 

To the members of 

## International Federation of Gynecology and Obstetrics 

## Other Information 

The other information comprises the information included in the trustees’ annual report other than the group financial statements and our auditor’s report thereon. The trustees are responsible for the other information contained within the annual report. Our opinion on the group financial statements does not cover the other information, and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the group financial statements or our knowledge obtained in the course of the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the group financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. 

We have nothing to report in this regard. 

## Opinions on other matters prescribed by the Companies Act 2006 

In our opinion, based on the work undertaken in the course of the audit: 

- The information given in the trustees’ annual report for the financial year for which the financial statements are prepared is consistent with the financial statements 

- The trustees’ annual report has been prepared in accordance with applicable legal requirements 

## Matters on which we are required to report by exception 

In the light of the knowledge and understanding of the group and the parent charitable company and their environment obtained in the course of the audit, we have not identified material misstatements in the trustees’ annual report. 

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 and Charities Act 2011 requires us to report to you if, in our opinion: 

- Adequate accounting records have not been kept by the parent charitable company, or returns adequate for our audit have not been received from branches not visited by us; or 

- The parent charitable company financial statements are not in agreement with the accounting records and returns; or 

- Certain disclosures of trustees’ remuneration specified by law are not made; or 

- We have not received all the information and explanations we require for our audit; or 

- The directors were not entitled to prepare the financial statements in accordance with the small companies regime and take advantage of the small companies’ exemptions in preparing the trustees’ annual report and from the requirement to prepare a strategic report. 

19 



Independent auditor’s report 

## To the members of 

## International Federation of Gynecology and Obstetrics 

## Responsibilities of trustees 

As explained more fully in the statement of trustees’ responsibilities set out in the trustees’ annual report, the trustees (who are also the directors of the parent charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. 

In preparing the financial statements, the trustees are responsible for assessing the group’s and the parent charitable company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the group or the parent charitable company or to cease operations, or have no realistic alternative but to do so. 

## Auditor’s responsibilities for the audit of the financial statements 

We have been appointed auditor under the Companies Act 2006 and section 151 of the Charites Act 2011 and report in accordance with those Acts. 

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements. 

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud are set out below. 

## Capability of the audit in detecting irregularities 

In identifying and assessing risks of material misstatement in respect of irregularities, including fraud and non-compliance with laws and regulations, our procedures included the following: 

- We enquired of management and trustees, which included obtaining and reviewing supporting documentation, concerning the group’s policies and procedures relating to: 

   - Identifying, evaluating, and complying with laws and regulations and whether they were aware of any instances of non-compliance; 

   - Detecting and responding to the risks of fraud and whether they have knowledge of any actual, suspected, or alleged fraud; 

20 



Independent auditor’s report 

## To the members of 

## International Federation of Gynecology and Obstetrics 

   - The internal controls established to mitigate risks related to fraud or non-compliance with laws and regulations. 

- We inspected the minutes of meetings of those charged with governance. 

- We obtained an understanding of the legal and regulatory framework that the group operates in, focusing on those laws and regulations that had a material effect on the financial statements or that had a fundamental effect on the operations of the group from our professional and sector experience. 

- We communicated applicable laws and regulations throughout the audit team and remained alert to any indications of non-compliance throughout the audit. 

- We reviewed any reports made to regulators. 

- We reviewed the financial statement disclosures and tested these to supporting documentation to assess compliance with applicable laws and regulations. 

- We performed analytical procedures to identify any unusual or unexpected relationships that may indicate risks of material misstatement due to fraud. 

- In addressing the risk of fraud through management override of controls, we tested the appropriateness of journal entries and other adjustments, assessed whether the judgements made in making accounting estimates are indicative of a potential bias and tested significant transactions that are unusual or those outside the normal course of business. 

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation.  This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation. 

A further description of our responsibilities is available on the Financial Reporting Council’s website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor’s report. 

## Use of our report 

This report is made solely to the charitable company's members as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006 and section 144 of the Charities Act 2011 and regulations made under section 154 of that Act. Our audit work has been undertaken so that we might state to the charitable company's members those matters we are required to state to them in an auditor’s report and for no other purpose. 

21 



Independent auditor’s report 

To the members of 

## International Federation of Gynecology and Obstetrics 

To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company's members as a body, for our audit work, for this report, or for the opinions we have formed. 

Joanna Pittman (Senior statutory auditor) 

22 August 2022 

for and on behalf of Sayer Vincent LLP, Statutory Auditor Invicta House, 108-114 Golden Lane, LONDON, EC1Y 0TL 

Sayer Vincent LLP is eligible to act as auditor in terms of section 1212 of the Companies Act 2006 

22 



## International Federation of Gynecology and Obstetrics 

Consolidated statement of financial activities (incorporating an income and expenditure account) 

For the year ended 31 December 2021 

|Unrestricted<br>Note<br>£<br>Income from:<br>11,369<br>381,856<br>-<br>1,437,107<br>629,988<br>2<br>86,979<br>2,547,299<br>-<br>1,878,247<br>3a<br>1,878,247<br>11<br>379,897<br>5<br>1,048,949<br>486,871<br>1,535,820<br>21<br>35,000<br>56,655<br>1,627,475<br>Reconciliation of funds:<br>4,873,844<br>6,501,319<br>Total funds brought forward<br>Total funds carried forward<br>669,052<br>Net income / (expenditure) for the year<br>Net gains /(losses) on investments<br>Charitable activities<br>Expenditure on:<br>Total income<br>Charitable activities<br>Raising funds<br>Journal<br>Net movement in funds<br>Net income / (expenditure) before other<br>recognised gains and losses<br>Actuarial gains on defined benefit pension schemes<br>Other gains/(losses) on foreign exchange<br>Transfers between Funds<br>Total expenditure<br>Net income / (expenditure) before net gains /<br>(losses) on investments<br>Membership<br>World Congress<br>Projects<br>Donations and legacies<br>Investments|Unrestricted<br>Note<br>£<br>Income from:<br>11,369<br>381,856<br>-<br>1,437,107<br>629,988<br>2<br>86,979<br>2,547,299<br>-<br>1,878,247<br>3a<br>1,878,247<br>11<br>379,897<br>5<br>1,048,949<br>486,871<br>1,535,820<br>21<br>35,000<br>56,655<br>1,627,475<br>Reconciliation of funds:<br>4,873,844<br>6,501,319<br>Total funds brought forward<br>Total funds carried forward<br>669,052<br>Net income / (expenditure) for the year<br>Net gains /(losses) on investments<br>Charitable activities<br>Expenditure on:<br>Total income<br>Charitable activities<br>Raising funds<br>Journal<br>Net movement in funds<br>Net income / (expenditure) before other<br>recognised gains and losses<br>Actuarial gains on defined benefit pension schemes<br>Other gains/(losses) on foreign exchange<br>Transfers between Funds<br>Total expenditure<br>Net income / (expenditure) before net gains /<br>(losses) on investments<br>Membership<br>World Congress<br>Projects<br>Donations and legacies<br>Investments|Restricted<br>£<br>-<br>-<br>5,195,509<br>-<br>-<br>-|2021<br>Total<br>£<br>11,369<br>381,856<br>5,195,509<br>1,437,107<br>629,988<br>86,979|Unrestricted<br>£<br>4,491<br>412,521<br>-<br>112,009<br>639,995<br>87,376|Restricted<br>£<br>-<br>-<br>4,716,043<br>-<br>-<br>-|2020<br>Total<br>£<br>4,491<br>412,521<br>4,716,043<br>112,009<br>639,995<br>87,376|
|---|---|---|---|---|---|---|
||2,547,299<br>-<br>1,878,247|5,195,509<br>-<br>4,211,772|7,742,808<br>-<br>6,090,019|1,256,392<br>20,291<br>1,458,943|4,716,043<br>-<br>4,192,415|5,972,435<br>20,291<br>5,651,358|
||1,878,247|4,211,772|6,090,019|1,479,234|4,192,415|5,671,649|
||379,897<br>669,052|-<br>983,737|379,897<br>1,652,789|(86,046)<br>(222,842)|-<br>523,628|(86,046)<br>300,786|
||1,048,949<br>486,871<br>1,535,820<br>35,000<br>56,655|983,737<br>(486,871)<br>496,866<br>-<br>-|2,032,686<br>-<br>2,032,686<br>35,000<br>56,655|(308,888)<br>149,372<br>(159,516)<br>15,000<br>(299,763)|523,628<br>(149,372)<br>374,256<br>-<br>-|214,740<br>-<br>214,740<br>15,000<br>(299,763)|
||1,627,475<br>4,873,844|496,866<br>1,916,603|2,124,341<br>6,790,447|(444,279)<br>5,318,123|374,256<br>1,542,347|(70,023)<br>6,860,470|
||6,501,319|2,413,469|8,914,788|4,873,844|1,916,603|6,790,447|



All of the above results are derived from continuing activities. There were no other recognised gains or losses other than those stated above. Movements in funds are disclosed in Note 18 to the financial statements. 

23 



International Federation of Gynecology and Obstetrics 

Company no. 05498067 

## Balance sheets 

## As at 31 December 2021 

|Note<br>Fixed assets:<br>10<br>11<br>Current assets:<br>14<br>Liabilities:<br>15<br>21<br>17a<br>18a<br>Total unrestricted funds<br>Net assets excluding pension liability<br>Funds:<br>Creditors: amounts falling due within one year<br>Net current assets<br>Total net assets<br>Restricted income funds<br>Unrestricted income funds:<br>Pension reserve<br>General funds<br>Defined benefit pension scheme surplus/(liability)<br>Designated Funds<br>Investments<br>Cash at bank and in hand<br>Tangible assets<br>Debtors<br>Total funds|2021<br>2020<br>£<br>£<br>1,044,740<br>1,072,523<br>3,225,239<br>2,754,789<br>4,269,979<br>3,827,312<br>708,835<br>303,353<br>4,670,681<br>4,347,197<br>5,379,516<br>4,650,550<br>(734,707)<br>(1,612,415)<br>4,644,809<br>3,038,135<br>8,914,788<br>6,865,447<br>-<br>(75,000)<br>8,914,788<br>6,790,447<br>2,413,469<br>1,916,603<br>1,094,339<br>1,121,988<br>5,406,980<br>3,826,856<br>-<br>(75,000)<br>6,501,319<br>4,873,844<br>8,914,788<br>6,790,447<br>The group|2021<br>2020<br>£<br>£<br>1,044,740<br>1,072,523<br>3,225,239<br>2,754,789<br>4,269,979<br>3,827,312<br>708,835<br>303,353<br>4,670,681<br>4,347,197<br>5,379,516<br>4,650,550<br>(734,707)<br>(1,612,415)<br>4,644,809<br>3,038,135<br>8,914,788<br>6,865,447<br>-<br>(75,000)<br>8,914,788<br>6,790,447<br>2,413,469<br>1,916,603<br>1,094,339<br>1,121,988<br>5,406,980<br>3,826,856<br>-<br>(75,000)<br>6,501,319<br>4,873,844<br>8,914,788<br>6,790,447<br>The group|2021<br>2020<br>£<br> £<br>1,043,898<br>1,071,400<br>3,225,240<br>2,754,790<br>4,269,138<br>3,826,190<br>1,804,480<br>493,705<br>3,505,457<br>4,036,718<br>5,309,937<br>4,530,423<br>(664,287)<br>(1,491,166)<br>4,645,650<br>3,039,257<br>8,914,788<br>6,865,447<br>-<br>(75,000)<br>8,914,788<br>6,790,447<br>2,413,469<br>1,916,603<br>1,093,497<br>1,120,865<br>5,407,822<br>3,827,979<br>-<br>(75,000)<br>6,501,319<br>4,873,844<br>8,914,788<br>6,790,447<br>The charity|2021<br>2020<br>£<br> £<br>1,043,898<br>1,071,400<br>3,225,240<br>2,754,790<br>4,269,138<br>3,826,190<br>1,804,480<br>493,705<br>3,505,457<br>4,036,718<br>5,309,937<br>4,530,423<br>(664,287)<br>(1,491,166)<br>4,645,650<br>3,039,257<br>8,914,788<br>6,865,447<br>-<br>(75,000)<br>8,914,788<br>6,790,447<br>2,413,469<br>1,916,603<br>1,093,497<br>1,120,865<br>5,407,822<br>3,827,979<br>-<br>(75,000)<br>6,501,319<br>4,873,844<br>8,914,788<br>6,790,447<br>The charity|
|---|---|---|---|---|
||4,269,979<br>708,835<br>4,670,681|3,827,312<br>303,353<br>4,347,197|4,269,138<br>1,804,480<br>3,505,457|3,826,190<br>493,705<br>4,036,718|
||5,379,516<br>(734,707)|4,650,550<br>(1,612,415)|5,309,937<br>(664,287)|4,530,423<br>(1,491,166)|
||4,644,809|3,038,135|4,645,650|3,039,257|
||8,914,788<br>-|6,865,447<br>(75,000)|8,914,788<br>-|6,865,447<br>(75,000)|
||8,914,788|6,790,447|8,914,788|6,790,447|
||2,413,469<br>1,094,339<br>5,406,980<br>-|1,916,603<br>1,121,988<br>3,826,856<br>(75,000)|2,413,469<br>1,093,497<br>5,407,822<br>-|1,916,603<br>1,120,865<br>3,827,979<br>(75,000)|
||6,501,319|4,873,844|6,501,319|4,873,844|
||8,914,788|6,790,447|8,914,788|6,790,447|



Approved by the trustees on 9th August 2022 and signed on their behalf by 

Dr Jeanne Conry President 

Dr Shantha Kumari Treasurer 

24 



International Federation of Gynecology and Obstetrics 

## Consolidated statement of cash flows 

## For the year ended 31 December 2021 

|Note<br>£<br>£<br>2,124,341<br>(56,655)<br>35,608<br>(379,897)<br>(86,979)<br>(405,482)<br>(877,708)<br>(75,000)<br>Net cash provided by/(used in) operating activities<br>278,228<br>86,979<br>(7,825)<br>35,813<br>(126,366)<br>(11,399)<br>266,829<br>4,347,197<br>56,655<br>4,670,681<br>(Increase)/decrease in debtors<br>(Decrease) in creditors<br>(Decrease) in pension liability<br>Cash flows from operating activities<br>Net cash (used in)/provided by investing activities<br>Cash flows from investing activities:<br>Dividends, interest and rents from investments<br>Purchase of fixed assets<br>Proceeds from sale of investments<br>Purchase of investments<br>Dividends, interest and rent from investments<br>Net income/(expenditure) for the reporting period<br>(as per the statement of financial activities)<br>Revaluation due to exchange rate movements<br>Depreciation charges<br>(Gains)/losses on investments<br>2021<br>Cash and cash equivalents at the beginning of the year<br>Cash and cash equivalents at the end of the year<br>Change in cash and cash equivalents in the year<br>Change in cash and cash equivalents due to exchange rate<br>movements|Note<br>£<br>£<br>2,124,341<br>(56,655)<br>35,608<br>(379,897)<br>(86,979)<br>(405,482)<br>(877,708)<br>(75,000)<br>Net cash provided by/(used in) operating activities<br>278,228<br>86,979<br>(7,825)<br>35,813<br>(126,366)<br>(11,399)<br>266,829<br>4,347,197<br>56,655<br>4,670,681<br>(Increase)/decrease in debtors<br>(Decrease) in creditors<br>(Decrease) in pension liability<br>Cash flows from operating activities<br>Net cash (used in)/provided by investing activities<br>Cash flows from investing activities:<br>Dividends, interest and rents from investments<br>Purchase of fixed assets<br>Proceeds from sale of investments<br>Purchase of investments<br>Dividends, interest and rent from investments<br>Net income/(expenditure) for the reporting period<br>(as per the statement of financial activities)<br>Revaluation due to exchange rate movements<br>Depreciation charges<br>(Gains)/losses on investments<br>2021<br>Cash and cash equivalents at the beginning of the year<br>Cash and cash equivalents at the end of the year<br>Change in cash and cash equivalents in the year<br>Change in cash and cash equivalents due to exchange rate<br>movements|Note<br>£<br>£<br>2,124,341<br>(56,655)<br>35,608<br>(379,897)<br>(86,979)<br>(405,482)<br>(877,708)<br>(75,000)<br>Net cash provided by/(used in) operating activities<br>278,228<br>86,979<br>(7,825)<br>35,813<br>(126,366)<br>(11,399)<br>266,829<br>4,347,197<br>56,655<br>4,670,681<br>(Increase)/decrease in debtors<br>(Decrease) in creditors<br>(Decrease) in pension liability<br>Cash flows from operating activities<br>Net cash (used in)/provided by investing activities<br>Cash flows from investing activities:<br>Dividends, interest and rents from investments<br>Purchase of fixed assets<br>Proceeds from sale of investments<br>Purchase of investments<br>Dividends, interest and rent from investments<br>Net income/(expenditure) for the reporting period<br>(as per the statement of financial activities)<br>Revaluation due to exchange rate movements<br>Depreciation charges<br>(Gains)/losses on investments<br>2021<br>Cash and cash equivalents at the beginning of the year<br>Cash and cash equivalents at the end of the year<br>Change in cash and cash equivalents in the year<br>Change in cash and cash equivalents due to exchange rate<br>movements|£<br>£<br>(70,023)<br>299,763<br>36,571<br>86,046<br>(87,376)<br>114,212<br>(373,373)<br>(17,000)<br>(11,180)<br>87,376<br>(2,508)<br>3,010,172<br>(2,983,461)<br>111,579<br>100,399<br>4,546,561<br>(299,763)<br>4,347,197<br>2020|£<br>£<br>(70,023)<br>299,763<br>36,571<br>86,046<br>(87,376)<br>114,212<br>(373,373)<br>(17,000)<br>(11,180)<br>87,376<br>(2,508)<br>3,010,172<br>(2,983,461)<br>111,579<br>100,399<br>4,546,561<br>(299,763)<br>4,347,197<br>2020|
|---|---|---|---|---|
||86,979<br>(7,825)<br>35,813<br>(126,366)||87,376<br>(2,508)<br>3,010,172<br>(2,983,461)||
||||||
|||4,670,681||4,347,197|



25 



International Federation of Gynecology and Obstetrics 

## Notes to the financial statements 

## For the year ended 31 December 2021 

## 1 Accounting policies 

## a) Statutory information 

International Federation of Gynecology and Obstetrics is a charitable company limited by guarantee and is incorporated in the United Kingdom. 

The registered office address is Suite 3, Waterloo Court, 10 Theed Street, London, SE1 8ST. 

## b) Basis of preparation 

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) - (Charities SORP FRS 102), The Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006. 

Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy or note. 

These financial statements consolidate the results of the charitable company and its wholly-owned subsidiary FIGO Trading Limited (company registration number 05895905) on a line by line basis. Transactions and balances between the charitable company and its subsidiary have been eliminated from the consolidated financial statements. Balances between the two companies are disclosed in the notes of the charitable company's balance sheet. A separate statement of financial activities, or income and expenditure account, for the charitable company itself is not presented because the charitable company has taken advantage of the exemptions afforded by section 408 of the Companies Act 2006. 

In applying the financial reporting framework, the trustees have made a number of subjective judgements, for example in respect of significant accounting estimates. Estimates and judgements are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.  The nature of the estimation means the actual outcomes could differ from those estimates. Any significant estimates and judgements affecting these financial statements are detailed within the relevant accounting policy below. 

- c) Public benefit entity 

The charitable company meets the definition of a public benefit entity under FRS 102. 

## d) Going concern 

The trustees consider that there are no material uncertainties about the charitable company's ability to continue as a going concern. FIGO now operates with a small deficit in non-congress years and also has sufficient free reserves to ensure continued efficient running of the core elements of the Charity. 

The trustees do not consider that there are any sources of estimation uncertainty at the reporting date that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next reporting period. 

## e) Income 

Income is recognised when the charity has entitlement to the funds, any performance conditions attached to the income have been met, it is probable that the income will be received and that the amount can be measured reliably. 

Income from government and other grants, whether ‘capital’ grants or ‘revenue’ grants, is recognised when the charity has entitlement to the funds, any performance conditions attached to the grants have been met, it is probable that the income will be received and the amount can be measured reliably and is not deferred. 

FIGO Society Member Affiliate Membership fees are accounted for on an accruals basis. 

Income from royalties and editorial support (IJGO) is recognised when the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably. 

Congress income is recognised as income in the year that the Congress takes place. Congress income received in advance is deferred until the year of the Congress. 

Income received in advance of the provision of a specified service is deferred until the criteria for income recognition are met. 

## f) Interest receivable 

- Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the charity; this is normally upon notification of the interest paid or payable by the bank. 

26 



International Federation of Gynecology and Obstetrics 

## Notes to the financial statements 

## For the year ended 31 December 2021 

- 1 Accounting policies (continued) 

## g) Fund accounting 

Restricted funds are to be used for specific purposes as laid down by the donor.  Expenditure which meets these criteria is charged to the fund. 

Unrestricted funds are donations and other incoming resources received or generated for the charitable purposes. 

Designated funds are unrestricted funds earmarked by the trustees for particular purposes. 

## h) Expenditure and irrecoverable VAT 

Expenditure is recognised once there is a legal or constructive obligation to make a payment to a third party, it is probable that settlement will be required and the amount of the obligation can be measured reliably. Expenditure is classified under the following activity headings: 

- Costs of raising funds relate to the costs associated with attracting donations and investment management costs. 

- Expenditure on charitable activities includes the costs of delivering its activities and services for its beneficiaries. In includes both costs that can be allocated directly to such activities and those costs of an indirect nature necessary to support them. 

- Other expenditure represents those items not falling into any other heading 

- Support costs are those functions that assist the work of the charity but do not directly undertake charitable activities. Support costs include staff costs, finance costs and governance costs that suport the charity's activities. These costs have been allocated to expenditure on charitable activities. Costs relating to a particular activity are allocated directly and others are apportioned based on an estimate of the proportion of time spent on staff on a specific project. 

Irrecoverable VAT is charged as a cost against the activity for which the expenditure was incurred. 

## i) Grants payable 

Grants payable are made to third parties in furtherance of the charity's objects. Single or multi-year grants are accounted for when either the recipient has a reasonable expectation that they will receive a grant and the trustees have agreed to pay the grant without condition, or the recipient has a reasonable expectation that they will receive a grant and that any condition attaching to the grant is outside of the control of the charity. 

Provisions for grants are made when the intention to make a grant has been communicated to the recipient but there is uncertainty about either the timing of the grant or the amount of grant payable. 

## j) Tangible fixed assets 

Items of equipment are capitalised where the purchase price exceeds £1,500. Depreciation costs are allocated to activities on the basis of the use of the related assets in those activities. Assets are reviewed for impairment if circumstances indicate their carrying value may exceed their net realisable value and value in use. Major components are treated as a separate asset where they have significantly different patterns of consumption of economic benefits and are depreciated separately over its useful life. 

Where fixed assets have been revalued, any excess between the revalued amount and the historic cost of the asset will be shown as a revaluation reserve in the balance sheet. 

Depreciation is provided at rates calculated to write down the cost of each asset to its estimated residual value over its expected useful life. The depreciation rates in use are as follows: 

- Long leasehold property Not depreciated as recoverable amount deeemed to exceed carrying value 

- ▪ Leasehold improvements 15 years - straight line 

- Office equipment 25% - reducing balance 

- Computer equipment 25% - straight line 

## k) Listed investments 

Investments are a form of basic financial instrument and are initially recognised at their transaction value and subsequently measured at their fair value as at the balance sheet date using the closing quoted market price. Any change in fair value will be recognised in the statement of financial activities. Investment gains and losses, whether realised or unrealised, are combined and shown in the heading “Net gains/(losses) on investments” in the statement of financial activities. The charity does not acquire put options, derivatives or other complex financial instruments. 

## l) Investments in subsidiaries 

Investments in subsidiaries are at cost. 

27 



International Federation of Gynecology and Obstetrics 

## Notes to the financial statements 

## For the year ended 31 December 2021 

## 1 Accounting policies (continued) 

## m) Debtors 

Trade and other debtors are recognised at the settlement amount due after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due. 

## n) Cash at bank and in hand 

Cash at bank and cash in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account. 

## o) Creditors and provisions 

Creditors and provisions are recognised where the charity has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors and provisions are normally recognised at their settlement amount after allowing for any trade discounts due. 

## p) Financial instruments 

The charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method. 

## q) Pensions 

FIGO participates in the Royal College of Obstetricians and Gynaecologists Pension Scheme (the scheme) a UK registered trustbased pension scheme that provides defined benefits linked to members final pensionable salaries and their period of service as a member of the scheme. The scheme closed to future accrual of defined benefits with effect from 31 December 2014. The trustees are responsible for running the scheme in accordance with the scheme's Trust Deed and Rules, which sets out their powers. The Trustees of the scheme are required to act in the best interests of the beneficaries of the scheme. 

There are three categories of pension scheme members: 

- In-service deferred members: currently employed by a participating employer. These members' pensions are based on their final pensionable salaries at retirement or earlier date of leaving the scheme. 

- Deferred members: those not currently employed by a participating employer and whose pension has not yet started. 

- Pensioner members: former members in receipt of pension 

The charity also participates in a defined contribution pension scheme for the employees who joined the charity after 2003. The assets of the scheme are held seperately from those of the charity. The cost of pension contributions for the defined contribution scheme are charged to the Statement of Financial Activities as they become payable. 

## r) Foreign currencies 

Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of the transaction. Exchange differences are included as support costs. 

Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Exchange differences on these conversions are included in other gains and losses. 

- 2 Income from investments 

|Income from investments|||
|---|---|---|
|Bank Interest<br>Investment Income|2021<br>Total<br>£<br>86,979|2020<br>Total<br>£<br>77,176<br>10,200|
||86,979|87,376|



All income from investments is unrestricted. 

28 



International Federation of Gynecology and Obstetrics 

Notes to the financial statements 

## For the year ended 31 December 2021 

## 3a Analysis of expenditure (current year) 

|Staff costs (Note 6)<br>Project costs<br>Grant making (Note 4)<br>Committees<br>Finance costs<br>Journal<br>Congress<br>Office costs<br>Staff Training & Development<br>IT costs<br>Audit and accountancy<br>Legal and professional<br>Investment manager costs<br>Recruitment fees<br>Official Representation<br>Trustees Meeting<br>FIGO Council<br>Communications Costs<br>Depreciation<br>Support Costs<br>Governance costs<br>Total expenditure 2021<br>Total expenditure 2020|Raising<br>funds<br>£<br>-<br>-<br>-<br>-<br>-<br>-<br>-<br>-<br>-<br>-<br>-<br>-<br>-<br>-<br>-<br>-<br>-<br>-<br>-|Charitable<br>activities<br>£<br>753,439<br>341,835<br>2,442,543<br>87,380<br>-<br>71,664<br>821,932<br>-<br>-<br>-<br>-<br>-<br>-<br>-<br>-<br>-<br>-<br>-<br>-|Governance<br>costs<br>£<br>-<br>-<br>-<br>-<br>-<br>-<br>-<br>-<br>-<br>-<br>1,324<br>-<br>-<br>-<br>-<br>-<br>-<br>-<br>-|Support<br>costs<br>£<br>1,208,948<br>-<br>-<br>-<br>(23,955)<br>-<br>-<br>157,402<br>4,956<br>27,676<br>-<br>51,453<br>-<br>19,649<br>34,812<br>-<br>-<br>53,354<br>35,607|2021<br>Total<br>2020<br>Total<br>£<br>£<br>1,962,387<br>2,079,993<br>341,835<br>712,232<br>2,442,543<br>1,980,121<br>87,380<br>118,504<br>(23,955)<br>11,100<br>71,664<br>76,435<br>821,932<br>214,303<br>157,402<br>153,255<br>4,956<br>6,537<br>27,676<br>35,798<br>1,324<br>46,927<br>51,453<br>61,582<br>-<br>20,291<br>19,649<br>12,643<br>34,812<br>18,046<br>-<br>17,122<br>-<br>4,064<br>53,354<br>66,125<br>35,607<br>36,571<br>6,090,019<br>5,671,649<br>-<br>-<br>-<br>-<br>6,090,019<br>5,671,649|
|---|---|---|---|---|---|
||-<br>-<br>-|4,518,793<br>1,569,902<br>1,324|1,324<br>-<br>(1,324)|1,569,902<br>(1,569,902)<br>-||
||-|6,090,019|-|-||
||20,291|5,651,358|-|-||



The low Finance Costs are related to the reversal of audit accruals from earlier years in this fiscal period. 

29 



International Federation of Gynecology and Obstetrics 

Notes to the financial statements 

## For the year ended 31 December 2021 

## 3b Analysis of expenditure (prior year) 

|Staff costs (Note 6)<br>Project costs<br>Grant making (Note 4)<br>Committees<br>Finance costs<br>Journal<br>Congress<br>Office costs<br>Staff Training & Development<br>IT costs<br>Audit and accountancy<br>Legal and professional<br>Investment manager costs<br>Recruitment fees<br>Official Representation<br>Trustees Meeting<br>FIGO Council<br>Chief Executive and trustee costs<br>Communications Costs<br>Depreciation<br>Support Costs<br>Governance costs<br>Total expenditure 2020|Raising<br>funds<br>£<br>-<br>-<br>-<br>-<br>-<br>-<br>-<br>-<br>-<br>-<br>-<br>-<br>20,291<br>-<br>-<br>-<br>-<br>-<br>-<br>-|Charitable<br>activities<br>£<br>931,983<br>712,232<br>1,980,121<br>118,504<br>-<br>76,435<br>214,303<br>-<br>-<br>-<br>-<br>-<br>-<br>-<br>-<br>-<br>-<br>-<br>-<br>-|Governance<br>costs<br>£<br>-<br>-<br>-<br>-<br>-<br>-<br>-<br>-<br>-<br>-<br>46,927<br>-<br>-<br>-<br>-<br>-<br>-<br>-<br>-<br>-|Support<br>costs<br>2020<br>Total<br>£<br>£<br>1,148,010<br>2,079,993<br>-<br>712,232<br>-<br>1,980,121<br>-<br>118,504<br>11,100<br>11,100<br>-<br>76,435<br>-<br>214,303<br>153,255<br>153,255<br>6,537<br>6,537<br>35,798<br>35,798<br>-<br>46,927<br>61,582<br>61,582<br>-<br>20,291<br>12,643<br>12,643<br>18,046<br>18,046<br>17,122<br>17,122<br>4,064<br>4,064<br>-<br>-<br>66,125<br>66,125<br>36,571<br>36,571<br>1,570,853<br>5,671,649<br>(1,570,853)<br>-<br>-<br>-<br>-<br>5,671,649|
|---|---|---|---|---|
||20,291<br>-<br>-|4,033,578<br>1,570,853<br>46,927|46,927<br>-<br>(46,927)||
||20,291|5,651,358|-||



30 



International Federation of Gynecology and Obstetrics 

## Notes to the financial statements 

## For the year ended 31 December 2021 

- 4 Grant making 

|4<br>Grant making|||
|---|---|---|
|Obstetrical Gynaecological Society Bangladesh<br>The Tanzania Midwives Association<br>National College of Obstetricians Gynecologists of Benin (CNGOB)<br>Society of Gynecologists and Obstetricians of Cameroon (SOGOC)<br>Societe de Gynecologie et d’Obstetrique de Cote d’Ivoire (SOGOCI)<br>Kenya Obstetrical and Gynaecological Society<br>Societé Malienne de Gynécologie Obstétrique (SOMAGO)<br>Associação Moçambicana de Obstetras e Ginecologistas (AMOG)<br>Sociedad Panamenã de Obstetricia y Ginecología (SPOG)<br>Sociedad Peruana de Obstetricia y Ginecología (SPOG)<br>Association of Obstetricians and Gynaecologists of Uganda (AOGU)<br>Zambia Association of Gynaecologists & Obstetricians (ZAGO)<br>Bangladesh Obstetrical & Gyn Soc  SAFOG<br>Federation of Obstetrics & Gynaecological Soc<br>India Health Action Trust<br>Kasturba Health Society, Sevagram<br>Kenya Obstetrical Gynaecological Society<br>Kisumu Medical & Education Trust, Kenya<br>Massachusetts General Hospital<br>Merck - Elimination of Cervical Cancer:  Pilot Projects<br>End Cervical Cancer Nigeria Initiative<br>Nepal Society of Obstetricians & Gynaecologis<br>All grants in both periods were to institutions.<br>5<br>Total<br>Combating Postpartum Haemorrhage (CPH)<br>This is stated after charging / (crediting):<br>Net income / (expenditure) for the year<br>Auditor's remuneration (excluding VAT):<br>Depreciation<br>Advocating for Safe Abortion (ASA)<br>Post Partum IUD Services<br>Foreign exchange gains or losses<br>Audit<br>VAT and Corporation Tax services|2021<br>£<br>-<br>-|2020<br>£<br>141,467<br>76,492|
||-<br>130,468<br>153,267<br>155,676<br>325,684<br>151,917<br>325,099<br>206,277<br>109,883<br>140,286<br>305,789|217,959<br>210,153<br>209,076<br>111,140<br>181,929<br>112,947<br>110,333<br>121,501<br>100,128<br>199,547<br>156,403|
||2,004,346<br>73,203<br>9,504<br>49,919<br>13,977<br>7,101<br>50,337<br>204,157|1,513,157<br>-<br>-<br>-<br>-<br>9,317<br>54,610<br>185,078|
||408,197<br>10,000<br>20,000|249,005<br>-<br>-|
||30,000|-|
||2,442,543|1,980,121|
||2021<br>£<br>35,608<br>12,832<br>17,000<br>(12,406)|2020<br>£<br>36,571<br>1,200<br>15,300<br>(13,385)|



31 



International Federation of Gynecology and Obstetrics 

## Notes to the financial statements 

## For the year ended 31 December 2021 

- 6 Analysis of staff costs, trustee remuneration and expenses, and the cost of key management personnel 

Staff costs were as follows: 

|Staff costs were as follows:|||
|---|---|---|
|Consultancy costs<br>Employer’s contribution to pension schemes<br>Group Life Assurance & Income Protection<br>Salaries and wages<br>Redundancy and termination costs<br>Social security costs|2021<br>£<br>1,527,805<br>20,204<br>30,343<br>60,240<br>172,864<br>150,931|2020<br>£<br>1,703,758<br>4,606<br>40,411<br>25,061<br>188,861<br>117,296|
||1,962,387|2,079,993|



The redundancy and termination costs were settled and paid at the balance sheet date. 

The following number of employees received employee benefits in excess of £60,000 (excluding employer pension costs and employer's national insurance) during the year between: 

|£90,000 - £99,999<br>£60,000 - £69,999<br>£70,000 - £79,999<br>£80,000 - £89,999<br>£140,000 - £150,000<br>£110,000 - £130,000<br>£150,000 - £160,000|2021<br>No.<br>-<br>1<br>1<br>-<br>1<br>1<br>1|2020<br>No.<br>1<br>1<br>2<br>1<br>-<br>2<br>-|
|---|---|---|



The total employee benefits (including pension contributions and employer's national insurance) of the key management personnel were £730,007 (2020: £807,742). 

Trustees' expenses represents the payment or reimbursement of travel and subsistence costs totalling £8,472 (2020: £30,928) incurred by 3 (2020: 6) members. 

## 7 Staff numbers 

The average number of employees (head count based on number of staff employed) during the year was 28 (2020: 27). 

## 8 Related party transactions 

There are no related party transactions to disclose for 2021 (2020: none). 

There are no donations from related parties which are outside the normal course of business and no restricted donations from related parties. 

## 9 Taxation 

The charity is exempt from corporation tax as all its income is charitable and is applied for charitable purposes.  The charity's trading subsidiary FIGO Trading Limited distributes available profits under Gift Aid to the parent charity.  Its charge to corporation tax in the year was £Nil (2020: £Nil) 

32 



International Federation of Gynecology and Obstetrics 

## Notes to the financial statements 

## For the year ended 31 December 2021 

|For the year ended 31 December 2021||||||
|---|---|---|---|---|---|
|10<br>At the end of the year<br>Additions in year<br>Charge for the year<br>Depreciation<br>At the end of the year<br>At the start of the year<br>Net book value<br>At the end of the year<br>At the end of the year<br>At the start of the year<br>At the end of the year<br>Net book value<br>At the start of the year<br>Additions in year<br>Cost<br>At the end of the year<br>At the start of the year<br>Cost<br>The group<br>Tangible fixed assets<br>The charity<br>At the start of the year<br>Depreciation<br>Charge for the year<br>At the start of the year|Long<br>leasehold<br>property<br>£<br>778,384<br>-|£<br>250,184<br>-<br>Leasehold<br>improvement|Computer<br>equipment<br>£<br>12,124<br>-|Office<br>equipment<br>£<br>195,276<br>7,825|Total<br>£<br>1,235,968<br>7,825|
||778,384|250,184|12,124|203,101|1,243,793|
||-<br>-|54,207<br>16,679|11,470<br>531|97,768<br>18,398|163,445<br>35,608|
||-|70,886|12,001|116,166|199,053|
||778,384|179,298|123|86,935|1,044,740|
||778,384|195,977|654|97,508|1,072,523|
||Long<br>leasehold<br>property<br>£<br>778,384<br>-|£<br>250,184<br>-<br>Leasehold<br>improvement|Computer<br>equipment<br>£<br>2,123<br>-|Office<br>equipment<br>£<br>170,154<br>7,825|Total<br>£<br>1,200,845<br>7,825|
||778,384|250,184|2,123|177,979|1,208,670|
||-<br>-|54,207<br>16,679|1,239<br>531|73,999<br>18,117|129,445<br>35,327|
||-|70,886|1,770|92,116|164,772|
||778,384|179,298|353|85,863|1,043,898|
||778,384|195,977|884|96,155|1,071,400|



The lease on the long leasehold property expires in 2990. This property is not depreciated as the recoverable amount is deemed to exceed the carrying value. 

All of the above assets are used for charitable purposes. 

33 



International Federation of Gynecology and Obstetrics 

## Notes to the financial statements 

## For the year ended 31 December 2021 

- 11 Listed investments 

|Listed investments|||||
|---|---|---|---|---|
|Listed<br>Other investment<br>Unlisted<br>Investments in subsidiaries registered in the UK<br>Net gain/(loss) on change in fair value<br>UK equities<br>Other Equities<br>Fair value at the start of the year<br>Additions at cost<br>Fair value at the end of the year<br>Disposal proceeds<br>CCLA Investment: COIF Charities Ethical Investment Fund<br>Investments comprise:|2021<br>2020<br>£<br>£<br>2,754,789<br>2,867,546<br>126,366<br>2,983,461<br>(35,813)<br>(3,010,172)<br>379,897<br>(86,046)<br>3,225,239<br>2,754,789<br>2021<br>2020<br>£<br>£<br>308,010<br>35,909<br>-<br>-<br>30,962<br>790<br>2,886,266<br>2,718,090<br>-<br>-<br>3,225,239<br>2,754,789<br>The group<br>The group||2021<br>2020<br>£<br>£<br>2,754,790<br>2,867,547<br>126,366<br>2,983,461<br>(35,813)<br>(3,010,172)<br>379,897<br>(86,046)<br>3,225,240<br>2,754,790<br>2021<br>2020<br>£<br>£<br>308,010<br>35,909<br>-<br>-<br>30,962<br>790<br>2,886,266<br>2,718,090<br>1<br>1<br>3,225,240<br>2,754,790<br>The charity<br>The charity||
||3,225,239|2,754,789|3,225,240|2,754,790|



## 12 Subsidiary undertaking 

The charitable company owns the whole of the issued ordinary share capital of FIGO Trading Limited, a company registered in England. The subsidiary is used for commercial activities, including the organisation of the Biennial Congress and publication of the International Journal. All activities have been consolidated on a line by line basis in the statement of financial activities. Available profits are gift aided to the charitable company. The trustees Dr Jeanne Conry,  Dr Shantha Kumari Sekaran, Professor Dame Lesley Regan, Professor Mary Ann Lumsden, Sean O'Donnell are also directors of the subsidiary.  A summary of the results 

|Retained earnings<br>Retained earnings brought forward<br>Profit on ordinary activities<br>Distribution under Gift Aid to parent undertaking<br>Gross profit<br>Funds<br>The aggregate of the assets, liabilities and funds was:<br>Liabilities<br>Profit on ordinary activities<br>Assets<br>Retained earnings carried forward<br>Turnover<br>Cost of sales<br>Amounts owed to the parent undertaking are shown in note 14.<br>Administrative expenses<br>Operating profit before taxation<br>Taxation|2021<br>£<br>2,070,100<br>(894,060)|2020<br>£<br>752,421<br>(289,888)|
|---|---|---|
||1,176,040<br>(327,918)|462,533<br>(272,009)|
||848,122<br>-|190,524<br>-|
||848,122|190,524|
||-<br>848,122<br>(848,122)|-<br>190,524<br>(190,524)|
||-|-|
||1,667,430<br>(1,667,430)|443,873<br>(443,873)|
||-|-|
||||



34 



International Federation of Gynecology and Obstetrics 

## Notes to the financial statements 

## For the year ended 31 December 2021 

- 13 Parent charity 

The parent charity's gross income and the results for the year are disclosed as follows: 

|Amounts due from group undertakings<br>The FIGO Charitable Foundation - USA<br>Result for the year<br>Debtors<br>Gross income<br>Other debtors<br>Trade debtors<br>Prepayments and accrued income|2021<br>2020<br>£<br>£<br>147,873<br>129,942<br>32,713<br>9,878<br>527,603<br>162,838<br>-<br>-<br>646<br>695<br>708,835<br>303,353<br>The group|2021<br>2020<br>£<br>£<br>147,873<br>129,942<br>32,713<br>9,878<br>527,603<br>162,838<br>-<br>-<br>646<br>695<br>708,835<br>303,353<br>The group|2021<br>£<br>6,520,151<br>2,121,798|2020<br>£<br>5,409,952<br>(69,912)|
|---|---|---|---|---|
||708,835|303,353|1,804,480|493,705|



## 14 Debtors 

## 15 Creditors: amounts falling due within one year 

|Creditors: amounts falling due within one year|||||
|---|---|---|---|---|
|Balance at the beginning of the year<br>Amount released to income in the year<br>Amount deferred in the year<br>Balance at the end of the year<br>Deferred income<br>Accruals<br>Taxation and social security<br>Trade creditors<br>Other creditors<br>Deferred income (note 16)|2021<br>2020<br>£<br>£<br>151,335<br>83,852<br>7,068<br>17,929<br>7,791<br>7,158<br>515,743<br>686,138<br>52,770<br>817,338<br>734,707<br>1,612,415<br>2021<br>2020<br>£<br>£<br>817,338<br>1,438,998<br>(4,027,903)<br>(4,933,714)<br>3,263,335<br>4,312,054<br>52,770<br>817,338<br>The group<br>The group||2021<br>2020<br>£<br>£<br>131,475<br>23,256<br>7,068<br>6,486<br>7,791<br>6,621<br>465,217<br>684,032<br>52,736<br>770,771<br>664,287<br>1,491,166<br>2021<br>2020<br>£<br>£<br>770,771<br>1,438,964<br>(3,981,370)<br>(4,895,563)<br>3,263,335<br>4,227,370<br>52,736<br>770,771<br>The charity<br>The charity||
||52,770|817,338|52,736|770,771|



## 16 Deferred income 

35 



International Federation of Gynecology and Obstetrics 

## Notes to the financial statements 

## For the year ended 31 December 2021 

17a Analysis of group net assets between funds (current year) 

|Tangible fixed assets<br>Defined benefit pension liability<br>Investments<br>Net current assets<br>Net assets at 31 December 2021|Unrestricted<br>General<br>£<br>-<br>3,225,239<br>2,201,741<br>-|Unrestricted<br>Designated<br>£<br>1,044,339<br>-<br>30,000<br>-|Restricted<br>funds<br>£<br>401<br>-<br>2,413,068<br>-|Total funds<br>£<br>1,044,740<br>3,225,239<br>4,644,809<br>-|
|---|---|---|---|---|
||5,426,980|1,074,339|2,413,469|8,914,788|



17b Analysis of group net assets between funds (prior year) 

|Net assets at 31 December 2020<br>Defined benefit pension liability<br>Investments<br>Net current assets<br>Tangible fixed assets|Unrestricted<br>General<br>£<br>-<br>2,754,789<br>1,072,067<br>(75,000)|Unrestricted<br>Designated<br>£<br>1,071,988<br>-<br>50,000<br>-|Restricted<br>funds<br>£<br>535<br>-<br>1,916,068<br>-|Total funds<br>£<br>1,072,523<br>2,754,789<br>3,038,135<br>(75,000)|
|---|---|---|---|---|
||3,751,856|1,121,988|1,916,603|6,790,447|



36 



International Federation of Gynecology and Obstetrics 

## Notes to the financial statements 

## For the year ended 31 December 2021 

- 18a Movements in funds (current year) 

|Movements in funds (current year)||||||
|---|---|---|---|---|---|
||||||At 31|
||At 1 January|Income &|Expenditure||December|
||2021|gains|& losses|Transfers|2021|
|Restricted funds:|£|£|£|£|£|
|Adenymosis|10,891|-|<br>(783)|-|10,108|
|Ask Dr FIGO - Silicon Valley Community|-|75,752|(32,679)||43,073|
|Congress 2012 USAid - Engender Health Support Grant|14,709|-|-|-|14,709|
|Fellowship Support Grant - Chien-Tien Hsu Foundation|5,917|-|-|-|5,917|
|Non Communicable Diseases|222,060|97,235|(15,039)|(66,684)|237,572|
|FIGO Working Group for Pre-Term Births - March of||||||
|Dimes Foundation Support Grant|19,174|-|-|-|19,174|
|FIGO Workshop on Young People - MSI Marie Stopes||||||
|International Support Grant|7,819|-|-|(7,819)|-|
|Fistula Activities - Engender Health Support Grant|177|-|-|-|177|
|Fistula Activities - Private Donor Grant|79,069|185,763|(15,870)|-|248,962|
|Guidelines on prevention of Cervical Cancer - GSK||||||
|Support Grant|46,732|-|-|-|46,732|
|Guidelines on prevention of Cervical Cancer - PATH||||||
|Support Grant|79,865|-|-|-|79,865|
|GSK - Vaccination in women|107,538|-|-|-|107,538|
|Merck - Elimination of Cervical Cancer:  Pilot Projects|86,905|-|(30,000)|-|56,905|
|ICI - Internationa Childbrith Initiative|2,018|21,848|(22,893)||973|
|Markku Seppala Ovidon Lecture - Ovidon Trust Grant|211,425|-|-|-|211,425|
|Maternal & Child Health Integrated Program - Jhpiego||||||
|Support Grant|5,065|-|-|-|5,065|
|Maternal & Newborn Health - PMNCH Latin America||||||
|Support Grant|16,300|-|-|-|16,300|
|Organisational capacity building - Bill and Melinda Gates||||||
|Foundation Support Grant|4,154|-|-|-|4,154|
|Combating Postpartum Haemorrhage - Bill and Melinda||||||
|Gates Foundation Support Grant|314,656|469,727|(504,282)||280,101|
|Post Partum IUD Services - US Donor Support Grant||||||
|(Phase 3)|412,368|-|-|(412,368)|-|
|Prevention of Post Partum Haemorrhage - Gynuity||||||
|Support Grant|3,711|-|-|-|3,711|
|Prevention of Post Partum Haemorrhage - Concept||||||
|Foundation|-|202,374|(160,709)||41,665|
|Prevention of Post Partum Haemorrhage - POPPHI||||||
|Support Grant|1,209|-|-|-|1,209|
|Prevention of Unsafe Abortion Working Group - Ipas||||||
|Support Grant|4,357|-|-|-|4,357|
|Advocating for Safe Abortion Project (ASA)|96,922|3,800,271|(3,121,850)|-|775,343|
|SRH Fund Donation|-|14,861|-||14,861|
|Texas Children Hospital - TCH|100,101|301,676|(285,815)||115,962|
|Working Group on Challenges on care of women during||||||
|labour and delivery|19,762|-|-|-|19,762|
|World Heath Organisation - WHO MEC Criteria|(706)|26,002|(21,852)||3,444|
|World Repoer - Gynuity Support grant|5,166|-|-|-|5,166|
|World Report on Women's Health - IPAS Support Grant|8,428|-|-|-|8,428|
|WSRR - Nordic Federation Support Grant|2,150|-|-|-|2,150|
|WSRR - SOGC Support Grant|6,256|-|-|-|6,256|
|African Federation of Obstetrics and Gynaecology|6,717|-|-|-|6,717|
|South Asia Federation of Obstetrics and Gynaecology|15,688|-|-|-|15,688|
|Total restricted funds|1,916,603|5,195,509|(4,211,772)|(486,871)|2,413,469|
|Unrestricted funds:||||||
|Designated Funds:||||||
|President's fund|50,000|-||(20,000)|30,000|
|President's reallocated Fund to ICI|-|||20,000|20,000|
|Fixed assets fund|1,071,988|-|-|(27,649)|1,044,339|
|Total designated funds|1,121,988|-|-|(27,649)|1,094,339|
|General funds|3,826,856|2,927,196|(1,861,592)|514,520|5,406,980|
|Total unrestricted funds|4,948,844|2,927,196|(1,861,592)|486,871|6,501,319|
|Pension fund|(75,000)|244,000|(169,000)|-|-|
|Total funds including pension fund|6,790,447|8,366,705|(6,242,364)|-|8,914,788|



The narrative to explain the purpose of each fund is given at the foot of the note below. 

37 



International Federation of Gynecology and Obstetrics 

## Notes to the financial statements 

## For the year ended 31 December 2021 

18b Movements in funds (prior year) 

|Movements in funds (prior year)||||||
|---|---|---|---|---|---|
|President's fund<br>Fixed assets fund<br>Total designated funds<br>HPV - Merck Support Group<br>Pension fund<br>Total funds including pension fund<br>General funds<br>World Heath Organisation - WHO MEC Criteria<br>World Repoer - Gynuity Support grant<br>World Report on Women's Health - IPAS Support Grant<br>WSRR - Nordic Federation Support Grant<br>African Federation of Obstetrics and Gynaecology<br>South Asia Federation of Obstetrics and Gynaecology<br>Unrestricted funds:<br>FIGO Working Group for Pre-Term Births - March of<br>Dimes Foundation Support Grant<br>Prevention of Unsafe Abortion Working Group - Ipas<br>Support Grant<br>Advocating for Safe Abortion Project (ASA)<br>Texas Children Hospital - TCH<br>Merck - Elimination of Cervical Cancer:  Pilot Projects<br>ICI - Internationa Childbrith Initiative<br>Markku Seppala Ovidon Lecture - Ovidon Trust Grant<br>Maternal & Child Health Integrated Program - Jhpiego<br>Support Grant<br>Maternal & Newborn Health - PMNCH Latin America<br>Support Grant<br>Organisational capacity building - Bill and Melinda Gates<br>Foundation Support Grant<br>Combating Postpartum Haemorrhage - Bill and Melinda<br>Gates Foundation Support Grant<br>Helping Mothers Survive: Bleeding after Birth Program -<br>Laerdal Foundation Support Grant<br>HPV - GSK Support Grant<br>GSK - Vaccination in women<br>Adenymosis<br>Restricted funds:<br>Prevention of Post Partum Haemorrhage - POPPHI<br>Designated Funds:<br>FIGO Workshop on Young People - MSI Marie Stopes<br>International Support Grant<br>Fistula Activities - Engender Health Support Grant<br>Fistula Activities - Private Donor Grant<br>Guidelines on prevention of Cervical Cancer - GSK<br>Support Grant<br>Guidelines on prevention of Cervical Cancer - PATH<br>Support Grant<br>Non Communicable Diseases<br>Congress 2012 USAid - Engender Health Support Grant<br>Fellowship Support Grant - Chien-Tien Hsu Foundation<br>Post Partum IUD Services - US Donor Support Grant<br>(Phase 3)<br>Prevention of Post Partum Haemorrhage - Gynuity<br>Total unrestricted funds<br>Working Group on Challenges on care of women during<br>WSRR - SOGC Support Grant|At 1 January<br>2020<br>£<br>10,891<br>14,709<br>5,917<br>206,211<br>5,508<br>7,819<br>177<br>92,715<br>46,732<br>79,865<br>129,372<br>107,538<br>86,905<br>-<br>-<br>1,628<br>231,425<br>5,065<br>16,300<br>4,154<br>-<br>254,504<br>3,711<br>1,209<br>4,357<br>141,947<br>18,997<br>19,762<br>524<br>5,166<br>8,428<br>2,150<br>6,256<br>6,717<br>15,688<br>|Income &<br>gains<br>£<br>-<br>-<br>-<br>48,678<br>19,010<br>-<br>-<br>-<br>-<br>-<br>-<br>-<br>-<br>-<br>-<br>1,536<br>-<br>-<br>-<br>-<br>643,812<br>861,685<br>-<br>-<br>-<br>2,817,979<br>303,285<br>-<br>20,058<br>-<br>-<br>-<br>-<br>-<br>-|Expenditure<br>& losses<br>£<br> <br>-<br>-<br>-<br>(32,829)<br>(5,344)<br>-<br>-<br>(13,646)<br>-<br>-<br>-<br>-<br>-<br>-<br>-<br>(1,146)<br>-<br>-<br>-<br>-<br>(329,156)<br>(703,821)<br>-<br>-<br>-<br>(2,863,004)<br>(222,181)<br>-<br>(21,288)<br>-<br>-<br>-<br>-<br>-<br>-|Transfers<br>£<br>-<br>-<br>-<br>-<br>-<br>-<br>-<br>-<br>-<br>-<br>(129,372)<br>(107,538)<br>(86,905)<br>107,538<br>86,905<br>-<br>(20,000)<br>-<br>-<br>-<br>-<br>-<br>-<br>-<br>-<br>-<br>-<br>-<br>-<br>-<br>-<br>-|At 31<br>December<br>2020<br>£<br>10,891<br>14,709<br>5,917<br>222,060<br>19,174<br>7,819<br>177<br>79,069<br>46,732<br>79,865<br>-<br>-<br>-<br>107,538<br>86,905<br>2,018<br>211,425<br>5,065<br>16,300<br>4,154<br>314,656<br>412,368<br>3,711<br>1,209<br>4,357<br>96,922<br>100,101<br>19,762<br>(706)<br>5,166<br>8,428<br>2,150<br>6,256<br>6,717<br>15,688|
||1,542,347|4,716,043|(4,192,415)|(149,372)|1,916,603|
||-<br>1,105,873|-<br>-|-<br>-|50,000<br>(33,885)|50,000<br>1,071,988|
||1,105,873<br>4,304,250|-<br>1,256,392|-<br>(1,867,043)|16,115<br>133,257|1,121,988<br>3,826,856|
||5,410,123|1,256,392|(1,867,043)|149,372|4,948,844|
||(92,000)|17,000|-|-|(75,000)|
||6,860,470|5,989,435|(6,059,458)|-|6,790,447|



38 



International Federation of Gynecology and Obstetrics 

Notes to the financial statements 

## For the year ended 31 December 2021 

## 18 Explanation of fund transfers 

## Purposes of restricted funds 

## Advocating for Safe Abortion 

A grant provided by an anonymous donor to raise the capacity of ten National Member Societies to be national leaders on sexual and reproductive health and rights and safe abortion. 

## Adenymosis - Menstrual Disorders Committee 

A grant provided by Abbvie for Adenomyosis Classification Project. 

Ask Dr FIGO - Silicon Valley Community Fund 

A grant provided by Silicon Valley for AskDrFigo Project. Congress USAid - Engender Health Support Grant 

A grant provided by USAid-Engender Health to support for fellowships at the FIGO World Congress. 

## Fellowship Support Grant - Chien-Tien Hsu foundation 

A grant made by the Chien-Tien Hsu Foundation to support FIGO's Fellowship Awards in Gynaecologic Oncology. 

FIGO Working Group for Pre-Term Births - March of Dimes Foundation Support Grant 

A grant made by the March of Dimes Foundation to support FIGO's prevention of pre-term birth activities. 

FIGO Workshop on Young People - MSI Marie Stopes International Support Grant 

A grant made by Marie Stopes International to support FIGO's prevention of maternal death activities. 

Fistula activities -  EngenderHealth Support Grant 

A donation made by EngenderHealth to support FIGO's fistula activities. 

Fistula activities - Private Donor/Texas Children's Hospital 

A donation made by a private individual and the Texas Children's hospital, to support FIGO's fistula activities. 

## Gestational Diabetes Initiative - Novo Nordisk Support Grant 

A grant provided by Novo Nordisk to support FIGO's activities in the improvement of health standards for pregnant women with diabetes. 

Global Maternal Nutrition Guidelines -  Abbott Nutrition Support Grant 

A grant made by Abbott Nutrition International to support FIGO's development and dissemination of evidence based guidelines on maternal nutrition. 

## Guidelines on prevention of Cervical Cancer - GSK Support Grant 

A grant provided by GSK to support the Charity's activities in the area of cervical cancer prevention, including the development and publication of guidelines for medical professionals. 

## Guidelines on prevention of Cervical Cancer - PATH Support Grant 

A grant provided by PATH to support the Charity's activities in the area of cervical cancer prevention, including the development and publication of guidelines for medical professionals. 

## Helping Mothers Survive: Bleeding after Birth Program - Laerdal Foundation Support Grant 

A grant provided by the Laerdal Foundation to support an initiative aimed at helping mothers survive bleeding after birth. Following a period of deep historical analysis it was discovered that an incorrect allocation of expenditure was applied a number of years ago, this has been rectified in the current year. 

## HPV - GSK Support Grant 

A grant from GSK Biomedicals to support FIGO's work in the area of HPV being undertaken under the auspices of the FIGO Committee on Gynaecologic Oncology. As discussed with the donor, the unspent funds have been transferred to a new restricted fund to be spent on Vaccination in women. 

## HPV - Merck Support Grant 

A grant from Merck & Co to support FIGO's work in the area of HPV being undertaken under the auspices of the FIGO Committee on Gynaecologic Oncology. As discussed with the donor, the unspent funds have been transferred to a new restricted fund to be spent on Elimination of cervical cancer. 

## GSK - Vaccination in women 

A GSK donation to support vaccination of pregnant women. 

## Merck - Elimination of Cervical Cancer:  Pilot Projects 

A grant to support the undertaking of pilot projects to determine future directions in our  aim to support work on the elimination of cervical cancer 

39 



International Federation of Gynecology and Obstetrics 

Notes to the financial statements 

## For the year ended 31 December 2021 

- 18 Purposes of restricted funds (continued) 

## The International Childbirth Initiative (ICI) 

This is a FIGO Charity funded project to ensure evidence based practice focusing on better (bio)-medical and psychosocial health outcomes for the MotherBaby-Family unit. 

## Markku Seppala Ovidon Lecture - Ovidon Trust 

A donation provided by the Ovidon Trust to support a key lecture within the FIGO World Congress Scientific Programme. 

## Maternal & Child Health Integrated Program - Jhpiego Support Grant 

A grant provided by Jhpiego to support the maternal and child health integrated program. 

## Maternal & Newborn Health - PMNCH Latin America Support Grant 

A grant provided by the Partnership for Maternal, Newborn & Child Health to support maternal and newborn health workshops in Latin America. 

## Needs Assessment - US Donor Support Grant 

A grant provided by a US donor foundation to support the activities of FIGO's initiative to conduct the first phase of a ten country safe abortion project. 

Non Communicable Diseases - Novo Nordisk, PerkinElmer, Abbott Nutrition, and FIGO 

Grants provided by Novo Nordisk, PerkinElmer, Abbott Nutrition, and FIGO to support FIGO's initiative to advocate internationally on the importance of addressing pregnancy and NCDs. 

Organisational Capacity Building - Bill and Melinda Gates Foundation Support Grant 

A grant provided by The Bill and Melinda Gates Foundation to support the Charity's Initiative on "Improving maternal and newborn health in low-resource countries through strengthening the role of obstetric and gynaecological national associations". 

## Post Partum IUD Services - US Donor Support Grant 

A grant provided by a US donor foundation to support the activities of FIGO's initiative to provide postpartum IUD services in selected countries/territories where it is felt the greatest need is evident. 

## Prevention of Post Partum Haemorrhage - Gates Foundation & Concept Foundation 

A grant provided by Gates Foundation to support the Charity's activities in the prevention and treatment of post-partum haemorrhage. 

Prevention of Post Partum Haemorrhage - Gynuity Support Grant 

A grant provided by Gynuity to support the Charity's activities in the promotion of the use of Misoprostol in the prevention and treatment of post-partum haemorrhage. 

## Prevention of Post Partum Haemorrhage - POPPHI Support Grant 

A grant provided by POPPHI to support the activities of the FIGO working group on the prevention of unsafe abortion. 

Prevention of Unsafe Abortion Working Group - lpas support group 

A grant provided by lpas to support the activities of the FIGO working group on the prevention of unsafe abortion. 

## Prevention of Unsafe Abortion Working Group - US Donor Support grant 

A grant provided by a US donor foundation to support the activities of the FIGO working  group on the prevention of unsafe abortion. 

## WHO MEC Criteria 

A grant provided by WHO to provide policy and decision-makers, the scientific community, and providers with global standards for developing or updating national guidelines on contraceptive use. The fund is currently negative but further funds are expected in the new year. 

Working Group of Challenges in the care of women during labour and delivery 

This funding has been provided by five Corporate donors to support the development of evidence-based recommendations and tools for care of pregnant women during labour and delivery. 

## World Report on Women's Health - Gynuity Support grant 

A grant provided by Gynuity to offset the costs of the World Report on Women's Health. 

## World Report on Women's Health - lpas Support Group 

A grant provided by Ipas to offset the costs of the World Report on Women's Health. 

## WSRR -  Nordic Federation Support Grant 

A grant provided by the Nordic Federation to support the activities of the FIGO Committee for Women's Sexual and Reproductive Rights. The grant was originally intended for the Pre Congress Workshop held in Santiago, Chile on 30-31 October, 2003 and follow up activities. 

40 



International Federation of Gynecology and Obstetrics 

## Notes to the financial statements 

## For the year ended 31 December 2021 

- 18 Purposes of restricted funds (continued) 

## WSRR -  SOGC Support Grant 

A grant provided by SOGC (The Society of Obstetricians and· Gynaecologists of Canada) to support the activities of the FIGO Committee for Women's Sexual and Reproductive Rights. The grant was originally provided to support the Pre Congress Workshop held in Santiago, Chile on 30-31 October, 2003 and follow up activities. 

## African Federation of Obstetrics and Gynaecology 

New Venture fund grant at the 21st FIGO Congress in Vancouver, Canada. 

## South Asia Federation of Obstetrics and Gynaecology 

Collaboration between FIGO and SAFOG in joint conference in Columbo, Sri Lanka. 

## Purposes of designated funds 

## President's fund 

The trustees have decided to set aside funds to undertake women’s health projects. 

## Fixed assets fund 

This fund represents the value of fixed assets not otherwise held within restricted funds. These have been designated as they are not freely available to be utilised for charitable activities. 

## 19 Operating lease commitments payable as a lessee 

The charity's total future minimum lease payments under non-cancellable operating leases is as follows for each of the following periods 

|periods|||
|---|---|---|
|Less than one year<br>One to five years|2021<br>2020<br>£<br>£<br>900<br>900<br>-<br>900<br>900<br>1,800<br>Equipment||
||900|1,800|



- 20 Legal status of the charity 

The charity is a company limited by guarantee and has no share capital.  The liability of each member in the event of winding up is limited to £1. 

41 



International Federation of Gynecology and Obstetrics 

Notes to the financial statements 

## For the year ended 31 December 2021 

- 21 Defined benefit pension scheme 

FIGO participates in the Royal College of Obstetricians and Gynaecologists Pension Scheme (the scheme) a UK registered trust-based pension scheme that provides defined benefits linked to members' final pensionable salaries and their period of service as a member of the Scheme. The Scheme closed to future accrual of defined benefits with effect from 31 December 2014. The Trustees are responsible for running the scheme in accordance with the Scheme's Trust Deed and Rules, which sets out their powers. The Trustees of the Scheme are required to act in the best interests of the beneficiaries of the Scheme. 

There are three categories of pension scheme members: 

- In-service deferred members: currently employed by a participating employer. These members' pensions are based on their final pensionable salaries at retirement or earlier date of leaving the scheme. 

- Deferred members: those not currently employed by a participating employer and whose pension has not yet started 

- Pensioner members: former members in receipt of pension 

The Trustees are required to carry out an actuarial valuation of the scheme every 3 years. The last actuarial valuation of the Scheme was performed by the Scheme Actuary foir the Trustees as at 1 April 2016. This valuation revealed a funding shortfall of £4.98 million. In respect of the deficit of the Scheme as at 1 April 2016, the Participating Employers agreed to pay: 

- a contribution of £1 million in April 2017 

- £49,600 per month between 1 April 2020 and 31 March 2024 

- £38,250 per month between 1 April 2024 and 31 March 2027 

FIGO is responsible for meeting 7.4% of these contributions. The funding deficit is expected to be eliminated by 31 March 2027, 11 years after the effective date of valuation. 

The employee benefit obligations recognised in the balance sheet are as follows: 

|Amounts in the balance sheet:<br>Surplus /(Deficit) in scheme<br>Liabilities<br>Assets<br>Restriction to realisable amount<br>Net Asset /(Liabilities)<br>Net interest expense<br>Present value of funded obligations<br>Fair value of plan assets<br>Total<br>Recognised on the balance sheet<br>Amounts recognised in net incoming resources are as follows:|2021<br>£'000<br>(1,866)<br>2,035|2020<br>£'000<br>(2,053)<br>1,978|
|---|---|---|
||169|(75)|
||(1,866)<br>2,035|(2,053)<br>1,978|
||169<br>(169)|(75)<br>-|
||-|(75)|
||2021<br>£'000<br>1|2020<br>£'000<br>2|
||1|2|



42 



International Federation of Gynecology and Obstetrics 

Notes to the financial statements 

## For the year ended 31 December 2021 

21 Defined benefit pension scheme (continued) 

Changes in the present value of the defined benefit obligation are as follows: 

|Changes in the present value of the defined benefit obligation are as follows:|||
|---|---|---|
|Net actuarial gain / (loss) on defined benefit pension scheme<br>Actuarial gain/(loss) on plan obligations<br>Actuarial (loss)/gain on plan assets<br>Restriction on realisable amount<br>Contributions by employer<br>Opening fair value of plan assets<br>Interest Income<br>Actuarial gains<br>Net position:<br>Interest Income<br>Benefits paid<br>Opening net position<br>Closing fair value of plan assets<br>Other<br>Changes in the fair value of plan assets are as follows:<br>Actuarial gains/(losses)<br>Actuarial (gains)/losses - Experience<br>Closing defined benefit obligation<br>Interest cost<br>Other<br>Actuarial (gains)/losses - change of basis<br>Benefits paid<br>Contributions by employer<br>Opening defined benefit obligation<br>Closing net position|2021<br>£'000<br>(2,053)<br>(24)<br>92<br>27<br>-<br>92|2020<br>£'000<br>(1,903)<br>(36)<br>(253)<br>82<br>8<br>49|
||(1,866)|(2,053)|
||2021<br>£'000<br>1,978<br>23<br>85<br>41<br>-<br>(92)|2020<br>£'000<br>1,811<br>34<br>186<br>4<br>(8)<br>(49)|
||2,035|1,978|
||2021<br>£'000<br>(75)<br>(1)<br>204<br>(169)<br>41|2020<br>£'000<br>(92)<br>(2)<br>15<br>-<br>4|
||-|(75)|
||2021<br>£'000<br>119<br>85|2020<br>£'000<br>(171)<br>186|
||204|15|



43 



International Federation of Gynecology and Obstetrics 

Notes to the financial statements 

## For the year ended 31 December 2021 

- 21 Defined benefit pension scheme (continued) 

Principal actuarial assumptions at the balance sheet date (expressed as weighted averages): 

|Total defined benefit (DB) assets<br>Investment:<br>Asset return less expected return on assets<br>Legal & General<br>Annuities<br>Trustee bank accounts/current assets<br>Plan assets<br>Defined benefit obligation<br>Surplsu/(deficit)<br>Life expectancy - Female (individual age 40 in 2021)<br>Amounts for the current and previous years are as follows:<br>Future pension increases<br>Consumer Price Inflation assumption<br>Life expectancy - Female (individual age 60 in 2021)<br>Life expectancy - Male (individual age 60 in 2021)<br>Discount rate at the end of the year<br>Statutory revaluation in deferment<br>Future salary increases<br>Life expectancy - Male (individual age 40 in 2021)<br>Retail Price Inflation assumption|2021<br>%<br>3.4%<br>2.9%<br>1.8%<br>2.5%<br>3.0%<br>2.4% - 3.3%<br>26.5 years<br>28.0 years<br>29.2 years<br>30.6 years|2020<br>%<br>2.9%<br>2.4%<br>1.2%<br>2.4%<br>2.9%<br>2.1% - 2.9%<br>26.6 years<br>28.1 years<br>29.1 years<br>30.6 years|2019<br>%<br>2.7%<br>1.9%<br>1.9%<br>1.9%<br>3.0%<br>1.8% - 2.7%<br>26.5 years<br>27.9 years<br>28.9 years<br>30.4 years|
|---|---|---|---|
|||2021<br>£'000<br>27,009<br>-<br>128|2020<br>£'000<br>26,115<br>-<br>259|
|||27,137|26,374|
|||2021<br>£'000<br>(1,866)<br>2,035<br>169<br>85|2020<br>£'000<br>(2,053)<br>1,978<br>(75)<br>186|



44